乙酰基-L-肉碱与肌萎缩侧索硬化症:当前证据和潜在用途。

IF 2.7 4区 医学 Q3 NEUROSCIENCES
Fabiola De Marchi, Sakthipriyan Venkatesan, Massimo Saraceno, Letizia Mazzini, Elena Grossini
{"title":"乙酰基-L-肉碱与肌萎缩侧索硬化症:当前证据和潜在用途。","authors":"Fabiola De Marchi, Sakthipriyan Venkatesan, Massimo Saraceno, Letizia Mazzini, Elena Grossini","doi":"10.2174/1871527322666230330083757","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The management of neurodegenerative diseases can be frustrating for clinicians, given the limited progress of conventional medicine in this context.</p><p><strong>Aim: </strong>For this reason, a more comprehensive, integrative approach is urgently needed. Among various emerging focuses for intervention, the modulation of central nervous system energetics, oxidative stress, and inflammation is becoming more and more promising.</p><p><strong>Methods: </strong>In particular, electrons leakage involved in the mitochondrial energetics can generate reactive oxygen-free radical-related mitochondrial dysfunction that would contribute to the etiopathology of many disorders, such as Alzheimer's and other dementias, Parkinson's disease, multiple sclerosis, stroke, and amyotrophic lateral sclerosis (ALS).</p><p><strong>Results: </strong>In this context, using agents, like acetyl L-carnitine (ALCAR), provides mitochondrial support, reduces oxidative stress, and improves synaptic transmission.</p><p><strong>Conclusion: </strong>This narrative review aims to update the existing literature on ALCAR molecular profile, tolerability, and translational clinical potential use in neurodegeneration, focusing on ALS.</p>","PeriodicalId":10456,"journal":{"name":"CNS & neurological disorders drug targets","volume":" ","pages":"588-601"},"PeriodicalIF":2.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Acetyl-L-carnitine and Amyotrophic Lateral Sclerosis: Current Evidence and Potential use.\",\"authors\":\"Fabiola De Marchi, Sakthipriyan Venkatesan, Massimo Saraceno, Letizia Mazzini, Elena Grossini\",\"doi\":\"10.2174/1871527322666230330083757\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The management of neurodegenerative diseases can be frustrating for clinicians, given the limited progress of conventional medicine in this context.</p><p><strong>Aim: </strong>For this reason, a more comprehensive, integrative approach is urgently needed. Among various emerging focuses for intervention, the modulation of central nervous system energetics, oxidative stress, and inflammation is becoming more and more promising.</p><p><strong>Methods: </strong>In particular, electrons leakage involved in the mitochondrial energetics can generate reactive oxygen-free radical-related mitochondrial dysfunction that would contribute to the etiopathology of many disorders, such as Alzheimer's and other dementias, Parkinson's disease, multiple sclerosis, stroke, and amyotrophic lateral sclerosis (ALS).</p><p><strong>Results: </strong>In this context, using agents, like acetyl L-carnitine (ALCAR), provides mitochondrial support, reduces oxidative stress, and improves synaptic transmission.</p><p><strong>Conclusion: </strong>This narrative review aims to update the existing literature on ALCAR molecular profile, tolerability, and translational clinical potential use in neurodegeneration, focusing on ALS.</p>\",\"PeriodicalId\":10456,\"journal\":{\"name\":\"CNS & neurological disorders drug targets\",\"volume\":\" \",\"pages\":\"588-601\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"CNS & neurological disorders drug targets\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/1871527322666230330083757\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS & neurological disorders drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1871527322666230330083757","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

背景:目的:因此,迫切需要一种更全面的综合方法。在各种新出现的干预重点中,调节中枢神经系统的能量、氧化应激和炎症正变得越来越有前景:方法:线粒体能量所涉及的电子泄漏尤其会产生与活性氧自由基相关的线粒体功能障碍,从而导致许多疾病的病因,如阿尔茨海默氏症和其他痴呆症、帕金森氏症、多发性硬化症、中风和肌萎缩性脊髓侧索硬化症(ALS):在这种情况下,使用乙酰左旋肉碱(ALCAR)等药物可为线粒体提供支持,减少氧化应激,改善突触传递:本综述旨在更新有关 ALCAR 分子特征、耐受性以及在神经退行性病变中的临床转化应用潜力的现有文献,重点关注 ALS。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Acetyl-L-carnitine and Amyotrophic Lateral Sclerosis: Current Evidence and Potential use.

Background: The management of neurodegenerative diseases can be frustrating for clinicians, given the limited progress of conventional medicine in this context.

Aim: For this reason, a more comprehensive, integrative approach is urgently needed. Among various emerging focuses for intervention, the modulation of central nervous system energetics, oxidative stress, and inflammation is becoming more and more promising.

Methods: In particular, electrons leakage involved in the mitochondrial energetics can generate reactive oxygen-free radical-related mitochondrial dysfunction that would contribute to the etiopathology of many disorders, such as Alzheimer's and other dementias, Parkinson's disease, multiple sclerosis, stroke, and amyotrophic lateral sclerosis (ALS).

Results: In this context, using agents, like acetyl L-carnitine (ALCAR), provides mitochondrial support, reduces oxidative stress, and improves synaptic transmission.

Conclusion: This narrative review aims to update the existing literature on ALCAR molecular profile, tolerability, and translational clinical potential use in neurodegeneration, focusing on ALS.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.10
自引率
3.30%
发文量
158
审稿时长
6-12 weeks
期刊介绍: Aims & Scope CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. CNS & Neurological Disorders - Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信